NCT03535948

Brief Summary

Outcome of Hodgkin lymphoma patients over than 60 years treated by chemotherapy and/or radiotherapy: retrospective analysis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2018

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 24, 2018

Completed
21 days until next milestone

Study Start

First participant enrolled

May 15, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 24, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2019

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

June 17, 2019

Status Verified

May 1, 2019

Enrollment Period

1.5 years

First QC Date

April 24, 2018

Last Update Submit

June 14, 2019

Conditions

Hodgkin Lymphoma, Adult

Outcome Measures

Primary Outcomes (1)

  • Progression-free survival

    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

    Time between diagnosis and progression or death - up to 100 weeks

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All Hodgkin lymphoma patients over 60 years treated between 2000 and 2013 by chemotherapy and/or radiotherapy in two university hospitals in France

You may qualify if:

  • Patients over than 60 years
  • Newly diagnosed Hodgkin lymphoma

You may not qualify if:

  • Data not available

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU Dijon

Dijon, 21000, France

Location

CHRU Nancy

Vandœuvre-lès-Nancy, 54500, France

Location

MeSH Terms

Conditions

Hodgkin Disease

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Lauriane Filliatre-Clement

    CHRU Nancy

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2018

First Posted

May 24, 2018

Study Start

May 15, 2018

Primary Completion

November 30, 2019

Study Completion

December 1, 2019

Last Updated

June 17, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations

FR(2)